Global Neurology Academy
The Global Neurology Academy (GNA) Series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
46-60 of 60
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
CME/CETreatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
Vera Bril, MD
Neelam Goyal, MD
Managing Side Effects in FcRn Therapy: Best Practices for gMG
MinuteCE®Managing Side Effects in FcRn Therapy: Best Practices for gMG
Vera Bril, MD
Nicholas J. Silvestri, MD
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
MinuteCE®Preventing Myasthenic Crisis: Early Signs and Critical Interventions
Vera Bril, MD
Hans Katzberg, MD
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
CME/CETreatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Vera Bril, MD
Jonathan Strober, MD
Vera Bril, MD
Nicholas J. Silvestri, MD
Hans Katzberg, MD
A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
MinuteCE®A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
Vera Bril, MD
Nicholas J. Silvestri, MD
- advertisement
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
MinuteCE®New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
Vera Bril, MD
Nicholas J. Silvestri, MD
Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
MinuteCE®Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
Vera Bril, MD
Nicholas J. Silvestri, MD
Ocular to Generalized MG: How and Why the Disease Evolves
MinuteCE®Ocular to Generalized MG: How and Why the Disease Evolves
Vera Bril, MD
Hans Katzberg, MD
Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles
MinuteCE®Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles
Vera Bril, MD
Nicholas J. Silvestri, MD
Diagnostic Advances in gMG: Effective Tools and Techniques
MinuteCE®Diagnostic Advances in gMG: Effective Tools and Techniques
Vera Bril, MD
Hans Katzberg, MD
Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management
MinuteCE®Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management
Vera Bril, MD
Hans Katzberg, MD
- advertisement
Factoring Solutions to the Management of Stroke Care in the Settings of Secondary Prevention and AF
CME/CE Broadcast ReplayFactoring Solutions to the Management of Stroke Care in the Settings of Secondary Prevention and AF
M. Edip Gurol, MD, MSc
Robin Novakovic, MD
Shadi Yaghi, MD
Jeffrey Weitz, MD
5 Things You Need to Know About Epilepsy & Depression
CME/CE5 Things You Need to Know About Epilepsy & Depression
Heidi M. Munger Clary, MD, MPH
Jay Salpekar, MD, FANPA
Cladribine Receives Positive CHMP Opinion for Relapsing MS Treatment
Global Neurology AcademyCladribine Receives Positive CHMP Opinion for Relapsing MS Treatment
